|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| 12345678910111213...3031» |
- | Trial completion, Enrollment change: ResPECT: The Respiratory Protection Effectiveness Clinical Trial (clinicaltrials.gov) - Apr 25, 2019
P=N/A, N=2862, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | N=1600 --> 2862
- ||||||| Trial completion, Enrollment change, Monotherapy, Head-to-Head: Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment (clinicaltrials.gov) - Apr 20, 2019
P3, N=260, Completed, Sponsor: EMS
Active, not recruiting --> Completed | N=1600 --> 2862 Recruiting --> Completed | N=120 --> 260
- | Trial completion, Enrollment change: Blood and Plasma Collection For Use in Future Clinical Trials (clinicaltrials.gov) - Mar 14, 2019
P=N/A, N=21, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=120 --> 260 Active, not recruiting --> Completed | N=200 --> 21
- | Trial completion, Trial completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Feb 20, 2019
P=N/A, N=19, Completed, Sponsor: Michael A. Thompson, MD, PhD
Active, not recruiting --> Completed | N=200 --> 21 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017
- | Trial completion: T-cell Response-Flu Risk in Older Adults (clinicaltrials.gov) - Feb 16, 2019
P=N/A, N=850, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017 Recruiting --> Completed
- | oseltamivir / Generic mfg.
Trial completion, Trial primary completion date: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults (clinicaltrials.gov) - Feb 5, 2019
P=N/A, N=716, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2019 --> Nov 2017
- | paracetamol / Generic mfg., ibuprofen / Generic mfg.
Trial completion: The Benefit and Harm of Fever Suppression by Antipyretics in Influenza (clinicaltrials.gov) - Jan 31, 2019
P4, N=300, Completed, Sponsor: The University of Hong Kong
Active, not recruiting --> Completed | Trial primary completion date: Jun 2019 --> Nov 2017 Recruiting --> Completed
- ||||| Naphcon-A (naphazoline HCl) / Novartis, Alervil (pheniramine maleate) / Incepta
Enrollment change: Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal (clinicaltrials.gov) - Jan 25, 2019
P3, N=132, Completed, Sponsor: EMS
Recruiting --> Completed N=212 --> 132
- | Enrollment change, Metastases: Pharma-Pen (Formerly Innoject) Auto-injectory TIV (clinicaltrials.gov) - Jan 23, 2019
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=212 --> 132 N=120 --> 0
- | Enrollment change: CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations (clinicaltrials.gov) - Oct 16, 2018
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=120 --> 0 N=800 --> 0
- | FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion, Enrollment change: FluEMIST: FluMist in Egg Allergic Patients (clinicaltrials.gov) - Oct 3, 2018
P1/2, N=17, Completed, Sponsor: Walter Reed Army Medical Center
N=800 --> 0 Recruiting --> Completed | N=200 --> 17
- | Phase classification: Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant (clinicaltrials.gov) - Oct 2, 2018
P1/2, N=49, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=200 --> 17 Phase classification: P=N/A --> P1/2
- | Trial completion: The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine (clinicaltrials.gov) - Sep 12, 2018
P2, N=480, Completed, Sponsor: Shanghai Institute Of Biological Products
Phase classification: P=N/A --> P1/2 Active, not recruiting --> Completed
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (clinicaltrials.gov) - Aug 31, 2018
P4, N=360, Completed, Sponsor: University of Witwatersrand, South Africa
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion, Adherence: Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients (clinicaltrials.gov) - Aug 21, 2018
P=N/A, N=3940, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed Recruiting --> Completed
- | oseltamivir / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection (clinicaltrials.gov) - Aug 7, 2018
P1, N=20, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018 | Trial primary completion date: May 2019 --> Jul 2018
- | Trial completion: VIP-H1N1: Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults (clinicaltrials.gov) - Jul 18, 2018
P2, N=450, Completed, Sponsor: Oswaldo Cruz Foundation
Recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018 | Trial primary completion date: May 2019 --> Jul 2018 Active, not recruiting --> Completed
- | Enrollment change: Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - Jul 16, 2018
P1/2, N=39, Completed, Sponsor: Adimmune Corporation
Active, not recruiting --> Completed N=30 --> 39
- | Trial completion date, Trial primary completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Jul 2, 2018
P=N/A, N=19, Active, not recruiting, Sponsor: Michael A. Thompson, MD, PhD
N=30 --> 39 Trial completion date: Nov 2017 --> Nov 2019 | Trial primary completion date: Nov 2017 --> Nov 2019
- | Trial completion: Efficacy of Sambucol in the Treatment of Influenza (clinicaltrials.gov) - Jun 12, 2018
P4, N=100, Completed, Sponsor: Hadassah Medical Organization
Trial completion date: Nov 2017 --> Nov 2019 | Trial primary completion date: Nov 2017 --> Nov 2019 Active, not recruiting --> Completed
- | oseltamivir / Generic mfg.
Enrollment change: Oseltamivir Randomised Controlled Efficacy Trial (clinicaltrials.gov) - Jun 7, 2018
P3, N=1190, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Active, not recruiting --> Completed N=700 --> 1190
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment change: High Dose Influenza Vaccine in Nursing Home - Pilot Study (clinicaltrials.gov) - Apr 18, 2018
P4, N=2957, Completed, Sponsor: Insight Therapeutics, LLC
N=700 --> 1190 N=210 --> 2957
- | Trial completion: Use of Probiotics to Prevent Influenza (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=1440, Completed, Sponsor: McMaster University
N=210 --> 2957 Active, not recruiting --> Completed
- oseltamivir / Generic mfg.
Trial completion date, Trial primary completion date: A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection (clinicaltrials.gov) - Apr 9, 2018
P1, N=20, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
- | Trial completion, Trial completion date, Trial primary completion date: Two-site Intradermal Influenza Vaccination in Elderly (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=180, Completed, Sponsor: Queen Saovabha Memorial Institute
Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019 Recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
- | FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion, Phase classification, Enrollment change: Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers (clinicaltrials.gov) - Apr 4, 2018
P, N=62, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 Recruiting --> Completed | Phase classification: PN/A --> P | N=100 --> 62
- | Phase classification: Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza (clinicaltrials.gov) - Apr 2, 2018
P, N=178, Completed, Sponsor: University of Maryland
Recruiting --> Completed | Phase classification: PN/A --> P | N=100 --> 62 Phase classification: P=N/A --> P
- ||||| Phase classification, Enrollment change: Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults (clinicaltrials.gov) - Mar 31, 2018
P, N=4197, Completed, Sponsor: Dalhousie University
Phase classification: P=N/A --> P Phase classification: P=N/A --> P | N=2400 --> 4197
- | oseltamivir / Generic mfg.
Phase classification, Enrollment change, Trial withdrawal: An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study. (clinicaltrials.gov) - Mar 19, 2018
P4, N=0, Withdrawn, Sponsor: McMaster University
Phase classification: P=N/A --> P | N=2400 --> 4197 Phase classification: P1 --> P4 | N=100 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion date, Trial primary completion date: ResPECT: The Respiratory Protection Effectiveness Clinical Trial (clinicaltrials.gov) - Mar 5, 2018
P=N/A, N=1600, Active, not recruiting, Sponsor: Johns Hopkins University
Phase classification: P1 --> P4 | N=100 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Jan 2019 | Trial completion date: Dec 2017 --> Jan 2019
- | paracetamol / Generic mfg., ibuprofen / Generic mfg.
Phase classification: The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine (clinicaltrials.gov) - Feb 7, 2018
P=N/A, N=104, Completed, Sponsor: Duke University
Trial primary completion date: Dec 2017 --> Jan 2019 | Trial completion date: Dec 2017 --> Jan 2019 Phase classification: P4 --> P=N/A
- | Fluzone (influenza vaccine) / Sanofi
Trial completion: Immune and Hormone Response to Influenza Vaccine (clinicaltrials.gov) - Jan 31, 2018
P4, N=103, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed
- || Trial primary completion date: Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom (clinicaltrials.gov) - Jan 16, 2018
P=N/A, N=9206, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Apr 2011 --> Oct 2010
- lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 16, 2018
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2011 --> Oct 2010 Trial primary completion date: Nov 2018 --> Feb 2017
- | Trial primary completion date: Influenza Vaccine Post Allogeneic Transplant (clinicaltrials.gov) - Dec 28, 2017
P=N/A, N=68, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Nov 2018 --> Feb 2017 Trial primary completion date: Jan 2012 --> Jun 2011
- |||| RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine) / Merck (MSD), Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Trial primary completion date: A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) (clinicaltrials.gov) - Dec 26, 2017
P3, N=2808, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jan 2012 --> Jun 2011 Trial primary completion date: Jul 2013 --> Dec 2012
- | New trial: The Effect of Proximity on Flu-Shot Participation (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=1801, Completed, Sponsor: National Bureau of Economic Research, Inc.
- | New trial: Blood and Plasma Collection For Use in Future Clinical Trials (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion, Enrollment change: Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Dec 19, 2017
P2, N=16, Completed, Sponsor: University of Colorado, Denver
Trial primary completion date: Jul 2013 --> Dec 2012 Active, not recruiting --> Completed | N=360 --> 16
- | Avonex (recombinant IFN-?-1a) / Biogen
Phase classification: A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers (clinicaltrials.gov) - Nov 18, 2017
P1, N=120, Completed, Sponsor: Biogen
Active, not recruiting --> Completed | N=360 --> 16 Phase classification: P=N/A --> P1
- | Enrollment change: Immune Response to Influenza Vaccination (clinicaltrials.gov) - Oct 24, 2017
P=N/A, N=82, Completed, Sponsor: The Cleveland Clinic
Phase classification: P=N/A --> P1 N=350 --> 82
- | oseltamivir / Generic mfg.
Enrollment closed: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults (clinicaltrials.gov) - Oct 24, 2017
P=N/A, N=800, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=350 --> 82 Recruiting --> Active, not recruiting
- || Fluarix (influenza virus trivalent vaccine) / GSK
Trial primary completion date: Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM (clinicaltrials.gov) - Sep 29, 2017
P4, N=77, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2011 --> Jul 2011
- | oseltamivir / Generic mfg.
Trial completion: The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection (clinicaltrials.gov) - Sep 29, 2017
P=N/A, N=215, Completed, Sponsor: Rambam Health Care Campus
Trial primary completion date: Jan 2011 --> Jul 2011 Recruiting --> Completed
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Flu Vaccine Against Childhood Pneumonia, Bangladesh (clinicaltrials.gov) - Sep 25, 2017
P3, N=3508, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Influenza Diagnosis, Treatment and Surveillance With Xpert Flu (clinicaltrials.gov) - Sep 18, 2017
P=N/A, N=2011, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed Enrolling by invitation --> Completed
- | Trial completion: VAX-002: Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics (clinicaltrials.gov) - Sep 12, 2017
P=N/A, N=33, Completed, Sponsor: Emory University
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- |||| Trial completion, Enrollment change, Combination therapy: A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection (clinicaltrials.gov) - Sep 11, 2017
P2, N=168, Completed, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Recruiting --> Completed | N=330 --> 168
- | Trial completion, Enrollment change, Trial primary completion date: Respiratory Virus Outpatient Study (FLU 002 Plus) (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=11719, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Completed | N=330 --> 168 Recruiting --> Completed | N=5000 --> 11719 | Trial primary completion date: Sep 2017 --> May 2017
- | Enrollment closed, Trial primary completion date: Use of Probiotics to Prevent Influenza (clinicaltrials.gov) - Aug 4, 2017
P=N/A, N=1440, Active, not recruiting, Sponsor: McMaster University
Recruiting --> Completed | N=5000 --> 11719 | Trial primary completion date: Sep 2017 --> May 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2017